Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Cinnamon Bark Syrup is a concentrated liquid extract containing 60-75% cinnamaldehyde and procyanidins that inhibit the NF-κB inflammatory pathway and activate Nrf2 antioxidant responses. The preparation enhances insulin sensitivity and glucose uptake while providing antimicrobial effects through bacterial cell wall disruption.
Reported Benefits (Provisional)
Origin & History
Cinnamon Bark Syrup is derived from Ceylon cinnamon (Cinnamomum verum), which is native to Sri Lanka, India, and Southeast Asia. This concentrated botanical matrix captures the essence and therapeutic compounds of true cinnamon. It is valued in functional nutrition as a natural sweetener with potent metabolic and digestive support.
Research Narrative (Provisional)
Scientific studies, accessible through databases like PubMed and ScienceDirect, support the efficacy of cinnamon's active compounds in promoting digestive health, blood sugar control, and anti-inflammatory effects. Research continues to validate its broad therapeutic applications.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Phytochemicals: Cinnamaldehyde, eugenol, polyphenols, flavonoids. - Vitamins: Vitamin A, Vitamin C. - Minerals: Calcium, magnesium, potassium. - Other: Dietary fiber.
Reported Mechanism (Provisional)
The primary bioactive compound cinnamaldehyde (60-75% concentration) inhibits NF-κB and AP-1 transcription factors to suppress inflammatory mediators and cancer cell proliferation. Procyanidins and cinnamic acid activate the Nrf2 pathway, enhancing cellular antioxidant and detoxification responses. These compounds also enhance glucose uptake and insulin sensitivity while disrupting bacterial cell walls and reducing biofilm formation in pathogens like S. mutans.
Clinical Narrative (Provisional)
Current evidence for cinnamon bark syrup relies primarily on preclinical studies rather than human clinical trials with specific dosages and outcomes. Mouse tumor models demonstrated reduced NF-κB activity and tumor size, while rat studies using 0.02% cinnamon for 12 weeks showed preserved nitric oxide levels and increased phosphorylated eNOS. Human randomized controlled trials specifically evaluating syrup formulations with quantified endpoints like HbA1c reductions are lacking. The therapeutic applications require further clinical investigation to establish efficacy and optimal dosing protocols.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.